Third strategic acquisition in 12 months advances SYSPRO's goal to deliver fully integrated, end-to-end digital manufacturing ERP and WMS solutions for global manufacturers and...
SUZHOU, China, Aug. 4, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN022, an independently...
CHICAGO, Aug. 1, 2025 /PRNewswire/ -- Experity, the national leader in on-demand healthcare solutions, today announced the appointment of Bobby Ghoshal as President and Chief...
The World Intelligent Vehicle Conference 2025 Kicks Off
CHONGQING, China, Aug. 1, 2025 /PRNewswire/ -- China's intelligent vehicle industry is embracing global cooperation with openness...
VANCOUVER, BC, Aug. 1, 2025 /PRNewswire/ - Kootenay Silver Inc. (TSXV: KTN) (OTCQX: KOOYF) (the "Company" or "Kootenay") is pleased to announce the filing...
NEW YORK and BENGALURU, India, Aug. 1, 2025 /PRNewswire/ -- Mphasis, (BSE: 526299; NSE: MPHASIS), an Information Technology (IT) solutions provider specializing in cloud and cognitive services, today...
Strategic acquisition strengthens Clinisys's leadership in laboratory informatics across the full spectrum of healthcare, life sciences, and public health.
BANGALORE, India and TUCSON, Ariz., Aug. 1,...
MONTREAL, July 31, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI® (tafasitamab) in combination with rituximab and lenalidomide for the treatment of adult patients with previously treated follicular lymphoma (FL). The supplemental application for the additional indication was selected for review under Project Orbis.
Business Highlights
Company registered its highest-ever first quarter revenue of Rs. 12,539 million on back of strong execution in Engineering & Polymer business segments
Reported highest...
VedTechBio enhances RxAgentAI platform; teams with US-based AlphaMeld to cut drug discovery time and co-develop therapies for rare and metabolic diseases.
ABUJA, Nigeria and NEWPORT BEACH, Calif., July 30, 2025 /CNW/ -- In a landmark collaboration aimed at accelerating innovation, capacity building, and digital transformation...
ABUJA, Nigeria and NEWPORT BEACH, Calif., July 30, 2025 /PRNewswire/ -- In a landmark collaboration aimed at accelerating innovation, capacity building, and digital transformation...
ABUJA, Nigeria and NEWPORT BEACH, Calif., July 30, 2025 /PRNewswire/ -- In a landmark collaboration aimed at accelerating innovation, capacity building, and digital transformation...